Because the overall average analyst price target of about $205 is only marginally above the recent share price, the $215 figure used here reflects a stricter calculation: the average of only the verified analyst targets that sit above the current price. Across 23 analysts polled by S&P Global, the full range runs from $180 to $228, with a consensus rating of "Hold" and an overall mean of roughly $205. The six above-price targets used to derive $215 were $200 (Roth MKM), $201 (Keefe Bruyette), $218 (J.P. Morgan), $222 (UBS), $224 (Evercore ISI), and $228 (Cantor Fitzgerald).
Sentiment is genuinely split. In October 2026, Cantor Fitzgerald ($228), Evercore ISI ($224), UBS ($222), and J.P. Morgan ($218) maintained Buy ratings, while Morgan Stanley cut its target to $180, Mizuho to $190, Goldman Sachs to $191, and Wells Fargo to $183, with Keefe Bruyette lifting its target to $201 while keeping a Market Perform view. The gap between the low and high targets is wide, and the mean is a statistical midpoint rather than a guarantee.
MRSH recently traded near $192, close to the top of a 52-week range of $156.60 to $202.70. Reaching $215 would require an advance of roughly 12%, which is best described as a substantial move for a low-beta, defensive business. The path would likely depend on a sustained recovery in commercial insurance pricing, a pickup in organic growth, and either multiple expansion or earnings growth exceeding current consensus, which projects roughly $10.49 in EPS (earnings per share) for 2026 and about $11.46 for 2027.
Marsh & McLennan is the world's largest insurance broker, operating through Marsh, Guy Carpenter, Mercer, and Oliver Wyman, which gives it diversified, fee-based revenue. Third-quarter results modestly beat expectations, with revenue of about $6.35 billion. The company also offers a roughly 2% dividend yield on a $0.90 quarterly payout. Keefe Bruyette has suggested large-account pricing may soon bottom, and several bullish analysts point to margin expansion, digital and AI-related client spending, and the firm's strong free cash flow as reasons to remain constructive.
The principal obstacle is a softening P&C pricing cycle. Keefe Bruyette expects incremental middle-market and small-account softness into 2027, while Morgan Stanley cited "tepid" growth ahead of third-quarter reporting. Valuation also matters: the stock trades at a P/E (price-to-earnings) ratio in the low-to-mid 20s, which leaves limited room for error if growth disappoints. The cluster of October target reductions, a "Hold" consensus, and roughly $8 million in insider selling over a recent three-month stretch all point to a cautious near-term backdrop.
The 52-week high near $202 to $203 acts as the clearest resistance level, and a decisive move above it would be an important step toward the $215 target. On the downside, the $180 area, where several analyst targets cluster, is a notable support zone, followed by the 52-week low near $156.60. The stock's sharp rebound from the mid-$170s toward $200 in October suggests improving momentum, but the $202–$203 zone remains untested on a sustained closing basis.
Analyst price targets typically reflect a roughly 12-month research horizon, though individual firms may apply different timeframes. The next major catalyst is fourth-quarter and full-year results, with the next earnings report estimated for late January 2027. Investors should also watch P&C pricing surveys, guidance commentary, analyst revisions, and interest-rate decisions from the FOMC (Federal Open Market Committee), since the commercial insurance environment and valuation multiples are both sensitive to these factors.
Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on shifting market conditions, technical behavior, and AI-driven analysis. For a stock like MRSH, where analyst views are divided, such signals can help traders spot changing trends, monitor positions, and discover opportunities more efficiently than manual screening. Traders seeking a data-driven complement to fundamental research can explore the signals to see how the model currently reads the stock's setup.
The $215 target is a demanding but not extreme objective, derived from the six verified analyst targets above the current price and requiring roughly a 12% move. It is supported by a diversified franchise, a modest earnings beat, and the possibility that insurance pricing stabilizes, but it is constrained by softening P&C conditions, tepid organic growth, a cautious "Hold" consensus, and wide disagreement among analysts. Whether MRSH can reach $215 will hinge on pricing trends, upcoming earnings, and whether valuation can hold while growth re-accelerates. No outcome is guaranteed.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, MRSH has been closely correlated with AJG. These tickers have moved in lockstep 82% of the time. This A.I.-generated data suggests there is a high statistical probability that if MRSH jumps, then AJG could also see price increases.
| Ticker / NAME | Correlation To MRSH | 1D Price Change % | ||
|---|---|---|---|---|
| MRSH | 100% | +1.26% | ||
| AJG - MRSH | 82% Closely correlated | +0.73% | ||
| BRO - MRSH | 81% Closely correlated | +1.25% | ||
| AON - MRSH | 80% Closely correlated | +0.17% | ||
| WTW - MRSH | 68% Closely correlated | +1.79% | ||
| RYAN - MRSH | 61% Loosely correlated | +0.47% | ||
More | ||||
| Ticker / NAME | Correlation To MRSH | 1D Price Change % |
|---|---|---|
| MRSH | 100% | +1.26% |
| MRSH (5 stocks) | 85% Closely correlated | -0.06% |
| Insurance Brokers/Services (22 stocks) | 68% Closely correlated | +0.22% |
| Insurance (119 stocks) | 64% Loosely correlated | +0.49% |